Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Insulin signalling: new target for Parkinson’s treatments?

Parkinson’s disease is the second most common neurodegenerative disease, and affects 2–3% of people aged 65 years and older.1 The number of affected people is expected to double between 2005 and 2030 as the world’s population ages, which will further increase the societal and economic burdens of the disease.1 Although in the past 20 years understanding of the molecular mechanisms underlying neuronal dysfunction and cell death in Parkinson’s disease has improved substantially and novel therapeutic targets have been identified, no treatments with proven disease-modifying efficacy have become available.